LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.150-2.320 for the period, compared to the consensus estimate of 2.160. The company issued revenue guidance of $235.4 million-$242.8 million, compared to the consensus revenue estimate of $240.2 million. LeMaitre Vascular also updated its Q1 2025 guidance to 0.480-0.530 EPS.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LMAT. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday. Finally, Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Price Performance

LMAT opened at $90.87 on Friday. LeMaitre Vascular has a 12 month low of $62.39 and a 12 month high of $109.58. The stock has a market capitalization of $2.04 billion, a P/E ratio of 49.01, a P/E/G ratio of 2.22 and a beta of 0.96. The business has a 50 day simple moving average of $96.90 and a 200-day simple moving average of $94.66.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. Research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.